Literature DB >> 30008023

An insight into the molecular genetics of a uveal melanoma patient cohort.

Susan Kennedy1, Michael Rice1, Sinead Toomey2, Noel Horgan1, Bryan T Hennessey2, Annemarie Larkin3.   

Abstract

BACKGROUND/AIMS: Uveal melanoma (UM) is a highly aggressive malignancy and presents a clinically significant unmet need in cancer therapeutics. The aim of this study was to identify previously unreported mutations in UM among an Irish cohort of patients which may have potential clinical relevance.
METHODS: DNA was extracted from 36 intraocular melanoma patient samples and 4 metastatic melanoma samples among the patient cohort by microdissection from formalin-fixed paraffin embedded tissue blocks and underwent genotyping to test for known single nucleotide polymorphisms in 42 cancer associated genes. These mutations were analysed using a custom-designed sequenom panel.
RESULTS: Using high-throughput genotyping, mutually exclusive GNAQ and GNA11 mutations were detected in 31 of 34 UM patients together with a number of non-synonymous changes in established cancer driver genes, PHLPP2, MET, PIK3R1 and IDH-1, variants which have not been previously associated with UM.
CONCLUSION: Given the lack of knowledge regarding the clinical relevance of the variants identified in this UM cohort and their likely pathogenic nature in other cancers, further studies of the functional impact of these variant mutations are warranted to establish possible previously, undescribed roles in UM pathogenesis, which may provide additional targets for future therapies.

Entities:  

Keywords:  Immunotherapy; Mutation; SNP genotyping; Targeted therapy; Unmet need; Uveal melanoma

Mesh:

Year:  2018        PMID: 30008023     DOI: 10.1007/s00432-018-2705-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  43 in total

Review 1.  Turning off AKT: PHLPP as a drug target.

Authors:  Alexandra C Newton; Lloyd C Trotman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

2.  Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT).

Authors:  Richard D Carvajal; Sophie Piperno-Neumann; Ellen Kapiteijn; Paul B Chapman; Stephen Frank; Anthony M Joshua; Josep M Piulats; Pascal Wolter; Veronique Cocquyt; Bartosz Chmielowski; T R Jeffry Evans; Lauris Gastaud; Gerald Linette; Carola Berking; Jacob Schachter; Manuel J Rodrigues; Alexander N Shoushtari; Delyth Clemett; Dana Ghiorghiu; Gabriella Mariani; Shirley Spratt; Susan Lovick; Peter Barker; Elaine Kilgour; Zhongwu Lai; Gary K Schwartz; Paul Nathan
Journal:  J Clin Oncol       Date:  2018-03-12       Impact factor: 44.544

3.  Mutational status of IDH1 in uveal melanoma.

Authors:  Patrick J Cimino; Yungtai Kung; Joshua I Warrick; Shu-Hong Chang; C Dirk Keene
Journal:  Exp Mol Pathol       Date:  2016-05-04       Impact factor: 3.362

Review 4.  HIF1A gene polymorphisms and human diseases: Graphical review of 97 association studies.

Authors:  I Gladek; J Ferdin; S Horvat; G A Calin; T Kunej
Journal:  Genes Chromosomes Cancer       Date:  2017-03-31       Impact factor: 5.006

5.  Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C.

Authors:  John Brognard; Matthew Niederst; Gloria Reyes; Noel Warfel; Alexandra C Newton
Journal:  J Biol Chem       Date:  2009-03-26       Impact factor: 5.157

6.  Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in three-dimensional cultures.

Authors:  Klara Valyi-Nagy; Bernadett Kormos; Mohamed Ali; Deepak Shukla; Tibor Valyi-Nagy
Journal:  Mol Vis       Date:  2012-03-02       Impact factor: 2.367

7.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

8.  Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4.

Authors:  Peter Johansson; Lauren G Aoude; Karin Wadt; William J Glasson; Sunil K Warrier; Alex W Hewitt; Jens Folke Kiilgaard; Steffen Heegaard; Tim Isaacs; Maria Franchina; Christian Ingvar; Tersia Vermeulen; Kevin J Whitehead; Christopher W Schmidt; Jane M Palmer; Judith Symmons; Anne-Marie Gerdes; Göran Jönsson; Nicholas K Hayward
Journal:  Oncotarget       Date:  2016-01-26

9.  Comparison of the c-MET gene amplification between primary tumor and metastatic lymph nodes in non-small cell lung cancer.

Authors:  Chun-Wei Xu; Wen-Xian Wang; Mei-Juan Wu; You-Cai Zhu; Wu Zhuang; Gen Lin; Kai-Qi Du; Yun-Jian Huang; Yan-Ping Chen; Gang Chen; Mei-Yu Fang
Journal:  Thorac Cancer       Date:  2017-06-07       Impact factor: 3.500

10.  SF3B1 mutations are associated with alternative splicing in uveal melanoma.

Authors:  Marc-Henri Stern; Richard Marais; Simon J Furney; Malin Pedersen; David Gentien; Amaury G Dumont; Audrey Rapinat; Laurence Desjardins; Samra Turajlic; Sophie Piperno-Neumann; Pierre de la Grange; Sergio Roman-Roman
Journal:  Cancer Discov       Date:  2013-07-16       Impact factor: 39.397

View more
  1 in total

Review 1.  GNAQ and GNA11 Genes: A Comprehensive Review on Oncogenesis, Prognosis and Therapeutic Opportunities in Uveal Melanoma.

Authors:  Paula Silva-Rodríguez; Daniel Fernández-Díaz; Manuel Bande; María Pardo; Lourdes Loidi; María José Blanco-Teijeiro
Journal:  Cancers (Basel)       Date:  2022-06-22       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.